Abstract | OBJECTIVE: DESIGN AND PATIENTS: Hyponatremic patients in the SALT-1 and SALT-2 studies with a diagnosis of SIADH were identified based on clinical diagnosis by individual study investigators. Subjects were randomized to receive oral placebo (n=52) or tolvaptan 15 mg daily, with further titration to 30 and 60 mg daily, if necessary, based on the response of serum [Na(+)] (n=58). RESULTS: In patients with SIADH, improvement in serum [Na(+)] was significantly greater (P<0.0001) with tolvaptan than placebo over the first 4 days of therapy as well as the entire 30-day study, with minimal side effects of increased thirst, dry mouth, and urination. Only 5.9% of tolvaptan-treated patients had overly rapid correction of hyponatremia as defined by current guidelines. After discontinuation of tolvaptan, serum [Na(+)] declined to values similar to placebo. A significant positive treatment effect favoring tolvaptan on the physical component, and a near-significant trend on the mental component, was found using the SF-12 Health Survey. Tolvaptan was associated with a significantly reduced incidence of fluid restriction. CONCLUSIONS: Results for the SIADH subgroup were analogous to those of the combined SALT population regarding efficacy and safety but demonstrated a greater improvement in the physical component of the SF-12 Health Survey than in the full mixed etiology SALT patient group.
|
Authors | Joseph G Verbalis, Suzanne Adler, Robert W Schrier, Tomas Berl, Qiong Zhao, Frank S Czerwiec, SALT Investigators |
Journal | European journal of endocrinology
(Eur J Endocrinol)
Vol. 164
Issue 5
Pg. 725-32
(May 2011)
ISSN: 1479-683X [Electronic] England |
PMID | 21317283
(Publication Type: Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Administration, Oral
- Aged
- Benzazepines
(administration & dosage, adverse effects)
- Dizziness
(chemically induced)
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Inappropriate ADH Syndrome
(blood, drug therapy, urine)
- Male
- Middle Aged
- Thirst
(drug effects, physiology)
- Tolvaptan
- Treatment Outcome
|